<DOC>
	<DOCNO>NCT01855139</DOCNO>
	<brief_summary>The objective NIS ass real-life setting , usage pattern associate outcomes management ( healthcare resource utilisation associate cost ) patient non-valvular AF treat Xarelto , accordance term European marketing authorization Belgian reimbursement criterion .</brief_summary>
	<brief_title>Belgian Real Life Non-interventional Study ( NIS ) Xarelto Non-valvular Atrial Fibrillation ( AF ) Patients Treated Prevention Stroke Systemic Embolism</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Adult patient ≥ 18 year old confirm diagnosis nonvalvular atrial fibrillation Patients must addition present least one follow risk factor : prior stroke , TIA ( transient ischemic attack ) nonCNS ( central nervous system ) systemic embolism leave ventricular ejection fraction &lt; 40 % symptomatic heart failure , New York Heart Association class 2 high age ≥75 year age ≥65 year combination either diabetes , coronary disease arterial hypertension Patients fulfil Belgian reimbursement criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-valvular atrial fibrillation</keyword>
	<keyword>Stroke</keyword>
	<keyword>Systemic embolism</keyword>
	<keyword>Oral anticoagulation</keyword>
	<keyword>Real-life setting</keyword>
	<keyword>Preventive measure</keyword>
</DOC>